Company : Kores (India) Limited

Category : Pharmaceutical Chemicals and Intermediates

Key Products : Manufacturer of high grade Active Pharmaceutical Ingredients and Pharmaceutical Intermediates

Kores (India) Limited - Pharmaceuticals & Chemicals Division of KORES Group, India was established in 1981.

 

Kores – Pharma Division has evolved itself to become a recognized manufacturer of high grade Active Pharmaceutical Ingredients and Pharmaceutical Intermediates. Driven by robust manufacturing processes and stringent quality norms, Kores specializes in producing Theophylline and its advanced derivatives, mucolytic expectorants, diabetic, cardiovascular drugs, key intermediates for Anticancer and Antiparkinson drugs at cGMP manufacturing facility located at Roha, Maharashtra, India.

 

 

The Company’s Administrative Office is based at Pawane, Navi Mumbai. Wherein the same premises it has got its own Research & Development Centre, approved by the Department of Science & Industrial Research, Ministry of Science & Technology, New Delhi, India.

 

 

Quality

 

 

Quality has always been company’s motto and with continuous efforts towards attaining the highest levels of quality have ensured that product specifications match with international standard.

 

 

The Company has an established Quality Assurance and Quality Control systems, which encompasses activities both manufacturing control as well as sampling, analysis and release of relevant raw materials, intermediates and Active Pharmaceutical Ingredients.

 

 

Keeping in mind the fast changing times, QC is well equipped with sophisticated equipments / instruments / systems / qualified personnel.

 

 

QA & RA ensures

 

 

• Implementation of Standard Operating Procedures and its periodic review.
• Process validation & Method validation
• In process controls
• Technology Transfer
• Documentation Control
• Auditing suppliers of critical raw materials.
• Handling deviations, customer complaints, implementation of corrective and preventive actions.
• Filing CTD DMF, CoS, Reach and other registrations required in various markets.
• Granted CEP (RO-CEP 2013-115-Rev 00) for Ambroxol HCl by EDQM.

 

 

 

Ambroxol HCL

Ambroxol Hydrochloride: It is a muco-active drug that posses several properties including secretolytic and secretomotoric actions in restoring the physiological clearance mechanisms of the respiratory tract, which play an important role in the body’s natural defense mechanisms. It stimulates synthesis and release of surfactant by type II pneumocytes. Surfactant acts as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, improving its transport and providing protection against infection and irritating agents. Ambroxol is often administered as an active ingredient in cough syrup.

Ambroxol is indicated as "secretolytic therapy” in broncho-pulmonary diseases associated with abnormal mucus secretion and impaired mucus transport. It promotes mucus clearance, facilitates expectoration and eases productive cough, allowing patients to breathe freely and deeply.

Doxofylline

Doxofylline: It is a novel xanthine broncho-dilator, which differs from Theophylline. Similarly to Theophylline, its mechanism of action is related to the inhibition of phosphodiesterase activities, but in contrast it appears to have decreased affinities towards adenosine A1 and A2 receptors, which may account for its better safety profile. The broncho-dilating activities of Doxofylline have been demonstrated in clinical trials involving patients with either bronchial asthma or chronic obstructive pulmonary disease. In contrast to other broncho-dilators, experimental and clinical studies have shown that the drug is devoid of direct stimulatory effects. This may be of importance because the arrhythmogenic actions of broncho-dilators may have a negative impact on the survival of patients with respiratory diseases.

Glimepiride

Glimepiride: It is an oral blood sugar-lowering drug is a class of medicines for controlling diabetes called sulfonylureas. Glimepiride is used in type 2 of diabetes, the most common type of diabetes that is found in 90% of people suffering from the disease. In type 2 diabetes, insulin does not required necessarily to control the blood sugar. Instead, diet and oral medications are often sufficient. Intolerance to diabetes that results in elevated blood sugar is caused by reduced insulin secretion by the pancreas and resistance to insulin's effects on the body's cells. Glimepiride lowers the sugar level in the blood by stimulating insulin to be secreted from the pancreas into the blood. Insulin causes sugar to leave the blood and enter cells throughout the body.

Ivabradine HCl

Ivabradine Hydrochloride: It is a novel medication used for the symptomatic management of stable angina pectoris.  Ivabradine is an effective anti-anginal and anti-ischemic drug, not inferior to the beta blocker atenolol and the calcium channel antagonist (CCA) amlodipine. It decreases the frequency of angina attacks and increases the time to anginal symptoms during exercise. Because of its exclusive chronotropic effect, Ivabradine is not associated with the typical adverse reactions associated with beta blockers or other anti-anginal drugs.

Bromhexine HCl

Bromhexine Hydrochloride: It is intended to support the body's mechanisms for clearing mucus from the respiratory tract.

It is secretolytic, increases the production of serous mucus in the respiratory tract and makes the phlegm thinner and less viscous. This contributes to a secretomotoric effect by helping the cilia transport the phlegm out of the lungs. For this reason it is often added to cough syrups.

Bromhexine is a synthetic derivative of the herbal active ingredient vaccine. It has been shown to increase the proportion of serous bronchial secretion, making it more easily expectorated. It is indicated as "secretolytic therapy in broncho-pulmonary diseases associated with abnormal mucus secretion and impaired mucus transport".

It is preferable to some cough medication as it does not include any sedatives, which can otherwise make those using the medication feel drowsy.

Contact Details

KORES (INDIA) LIMITED
(Pharmaceuticals & Chemicals Division)
C-7/1-B, TTC Industrial Area,
MIDC-Pawane,Navi Mumbai – 400706.
Tel: +91 22 27613455 / 61389035
Fax: +91 22 27613466 / 61389039
e-Mail: info@korescd.com
/ pcd.marketing@kores-india.com
URL: www.korescd.com